Antiretroviral treatment of primary HIV infection to reduce onward transmission

Current Opinion in HIV and AIDS

Volumn 5, Issue 4, 2010, Pages 283-290

  Hamlyn, Elizabeth ^a   Jones, Vicky ^a   Porter, Kholoud ^a   Fidler, Sarah ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antiretroviral therapy; Primary HIV infection; Transmission prevention

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ANTIGEN; VIRUS RNA;

ADVERSE OUTCOME; ANTIGEN ANTIBODY COMPLEX; BEHAVIOR MODIFICATION; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CHRONIC DISEASE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE TRANSMISSION; EARLY INTERVENTION; ENZYME IMMUNOASSAY; EPIDEMIC; FALSE POSITIVE RESULT; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENETIC VARIABILITY; GENOME ANALYSIS; GLYCOSYLATION; HOST SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; LYMPHOID TISSUE; MACACA; MALE HOMOSEXUAL; MATHEMATICAL MODEL; MOLECULAR PHYLOGENY; NONHUMAN; PHARMACOGENOMICS; PRIMARY INFECTION; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; SHORT COURSE THERAPY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENETICS; VIRION; VIROGENESIS; VIRUS ISOLATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION;

ANIMALS; ANTI-RETROVIRAL AGENTS; CHEMOPREVENTION; DISEASE TRANSMISSION, INFECTIOUS; HIV; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; PHYLOGENY; PRIMATE DISEASES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

EID: 77953581594     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32833a6b11     Document Type: Review

References (83)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929.
2. Morrison CS, Demers K, Kwok C, et al. Plasma and cervical viral loads among Ugandan and Zimbabwean women during acute and early HIV-1 infection. AIDS 2010; 24:573-582.
3. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273-1289.
4. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959.
5. Pao D, Fisher M, Hue S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85-90.
6. Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723-1730.
7. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis 2008; 198:687-693.
8. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 2010; 23:26-31.
9. Chisembele M, Crook A, Gafos M, et al., MDP Team. PRO2000 vaginal gel is ineffective in preventing HIV infection: results of the MDP301 phase III microbicide trial [abstract #87LB]. In: 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
10. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005; 40:96-101.
11. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
12. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729-735.
13. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601.
14. Gazzard BG, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
15. WHO. New HIV recommendations to improve health, reduce infections and save lives. http://www.who.int/mediacentre/news/releases/2009/world- aids-20091130/en/index.html. [Accessed 13th March 2010]
16. Porche DJ. Condom effectiveness. J Assoc Nurses AIDS Care 1998; 9:91-94.
17. Wagner GJ, Holloway I, Ghosh-Dastidar B, et al.. Factors associated with condom use among HIV clients in stable relationships with partners at varying risk for HIV in Uganda. AIDS Behav 2010. [Epub ahead of print]
18. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009; 323:1304-1307.
19. Shacklett BL, Anton PA. HIV infection and gut mucosal immune function: updates on pathogenesis with implications for management and intervention. Curr Infect Dis Rep 2010; 12:19-27.
20. McMichael AJ, Borrow P, Tomaras GD, et al. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev 2010; 10:11-23.
21. Picker LJ. Immunopathogenesis of acute AIDS virus infection. Curr Opin Immunol 2006; 18:399-405.
22. Keele BF, Derdeyn CA. Genetic and antigenic features of the transmitted virus. Curr Opin HIV AIDS 2009; 4:352-357.
23. Kearney M, Maldarelli F, Shao W, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 2009; 83:2715-2727.
24. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol 2005; 79:6528-6531.
25. Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol 2006; 4:312-317.
26. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192:466-474.
27. Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the preramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288-3297.
28. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552-7557.
29. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098-3107.
30. Shaw G. Transmitted founder viruses and their progeny in acute HIV-1 and SIV infection [Plenary presentation abstract #20]. In: 17th Conference on retroviruses and opportunistic infections; San Francisco; 2010.
31. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 2009; 83:3556-3567.
32. Sagar M, Laeyendecker O, Lee S, et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis 2009; 199:580-589.
33. Frater AJ, Edwards CT, McCarthy N, et al. Passive sexual transmission of human immunodeficiency virus type 1 variants and adaptation in new hosts. J Virol 2006; 80:7226-7234.
34. Hecht FM, Hartogensis W, Bragg L, et al. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 2010; 24:941-945.
35. Fox J, Fidler S. Sexual transmission of HIV-1. Antivir Res 2010; 85:276-285.
36. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571.
37. Mayaud P, Legoff J, Weiss HA, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebocontrolled trial. J Infect Dis 2009; 200:216-226.
38. White RG, Freeman EE, Orroth KK, et al. Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect 2008; 84 (Suppl 2):ii12-ii18.
39. White RG, Moodley P, McGrath N, et al. Low effectiveness of syndromic treatment services for curable sexually transmitted infections in rural South Africa. Sex Transm Infect 2008; 84:528-534.
40. Celum C, Wald A, Hughes J, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119.
41. Senior K. Back to basics for HIV vaccine research. Lancet Infect Dis 2008; 8:467.
42. British HIV Association. UK National Guidelines for HIV Testing 2008; 16 December 2009. http://www.bhiva.org/documents/Guidelines/Testing/ GlinesHIVTest08. pdf. [Accessed 13 March 2010]
43. Winter AJ, Sulaiman Z, Hawkins D. BASHH Clinical Governance Committee guidance on the appropriate use of HIV point of care tests. Int J STD AIDS 2006; 17:802-805.
44. Patel P, Bennett B, Sullivan T, et al., CDC AHI Study Group. Rapid HIV screening: missed opportunities for diagnosis and prevention [abstract #1002]. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
45. Patel P, Mackellar D, Simmons P, et al. Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006- 2008. Arch Intern Med 2010; 170:66-74.
46. O Laeyendecker, A Oliver, Astemborski J, et al.. Improved precision of crosssectional HIV incidence testing using a multiassay algorithm that includes BED and an avidity assay with modified assay cut-offs [abstract #935]. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
47. Fourth generation point of care HIV screening; 2010. http://www.cli- online.- com/featured-articles/fourth-generation-point-of-care-hiv-screening/ index. html. [Accessed 13 March 2010]
48. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879.
49. Sakarovitch C, Rouet F, Murphy G, et al. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J Acquir Immune Defic Syndr 2007; 45:115-122.
50. Health Protection Agency. HIV in the United Kingdom: 2009 Report. http:// www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb-C/ 1259151891866?p= 1249920575999. [Accessed 13 March 2010]
51. Fisher M, Pao D, Murphy G, et al. Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS 2007; 21:2309-2314.
52. Chawla A, Murphy G, Donnelly C, et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clinic Microbiol 2007; 45:415-420.
53. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS 2007; 21:1625-1629.
54. Jacquez JA, Koopman JS, Simon CP, Longini IM Jr. Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr 1994; 7:1169-1184.
55. Hayes RJ, White RG. Amplified HIV transmission during early-stage infection. J Infect Dis 2006; 193:604-605. [author reply 605-606].
56. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:249-258.
57. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409.
58. Abu-Raddad LJ, Longini IM Jr. No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS 2008; 22:1055-1061.
59. Jones V, Porter K, Hart G. How high is viral load in HIV seroconverters once they present to a clinic? [Abstract #P145]. 15th Annual Conference of the British HIV Association; Liverpool; 2009.
60. UNAIDS. AIDS Epidemic Update. http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf. [Accessed 13th March 2010]
61. Van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009; 4:300-307.
62. Hall HI, Geduld J, Boulos D, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr 2009; 51 (Suppl 1):S13-S20.
63. Karon JM, Song R, Brookmeyer R, et al. Estimating HIV incidence in the United States from HIV/AIDS surveillance data and biomarker HIV test results. Stat Med 2008; 27:4617-4633.
64. Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000- 2006: a systematic review. PLoS Med 2007; 4:e339.
65. Brown AE, Gifford RJ, Clewley JP, et al. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis 2009; 199:427-431.
66. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-129.
67. Fox J, White PJ, Macdonald N, et al. Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med 2009; 10:432-438.
68. Short Pulse AntiRetroviral Therapy at HIV seroConversion (SPARTAC); 2006. www.ctu.mrc.ac.uk/studies/spartac.asp.
69. Cellerai C, Little SJ, Loes SK. Treatment of acute HIV-1 infection: are we getting there? Curr Opin HIV AIDS 2008; 3:67-74.
70. Hogan C, DeGrutolla V, Daar E, et al., the A5217 Study Team. A finite course of ART during early HIV-1 infection modestly delays need for subsequent ART initiation: ACTG A5217, the SETPOINT study [abstract #134]. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
71. Fidler S, Fox J, Porter K, Weber J. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 2008; 21:4-10.
72. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005; 192:607-617.
73. Fidler S, Ewings F, Porter K, et al. for the SPARTAC and INSIGHT SMART collaborations A Comparison of HIV Viral Rebound Following ART Cessation in Primary (SPARTAC) and Chronic (SMART) HIV Infection [abstract #474]. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
74. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
75. Hamlyn E, Boyd K, Porter K, et al., the SPARTAC Trial Investigators. Interleukin- and D-dimer in primary HIV infection: effect of short course ART and treatment discontinuation [abstract #473]. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco; 2010.
76. Strategic Timing of Antiretroviral Treatment (START) http:// clinicaltrials.gov/ ct2/show/NCT00867048?term=start+trial+HIV&rank=1. [Accessed 13 March 2010]
77. Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009; 72:1465-1472.
78. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/ AIDS Rep 2007; 4:135-140.
79. Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS 2008; 3:653-659.
80. Latinovic O, Kuruppu J, Davis C, et al. Pharmacotherapy of HIV-1 infection: focus on CCR5 antagonist Maraviroc. Clin Med 2009; 1:1497-1510.
81. Dumond JB, Patterson KB, Pecha AL, et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:546-553.
82. Chueca N, Garrido C, Alvarez M, et al. Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. J Med Virol 2009; 81:763-767.
83. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-223.